Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab and Envafolimab Plus mFOLFOXIRI vs Cetuximab Plus mFOLFOX6 in First-line mCRC
NCT05959356Phase 2Recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Nov 2023
- Primary completion
- Dec 2026
- Modality
- Nanobodies (VHH), Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of envafolimab in metastatic colorectal cancer (mCRC), sponsored by Sun Yat-sen University. Started Nov 2023; status: recruiting.
02
Drugs
envafolimab
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT05959356.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05959356.